Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis
Sponsor: University Hospital, Clermont-Ferrand
Summary
Mucosal healing is recognized hitherto as the best therapeutic endpoint in patients with Ulcerative Colitis (UC) but its use in daily practice is limited by the low acceptability of repeated colonoscopies. In this context, fecal biomarkers are attractive alternatives. Fecal calprotectin showed very good negative predictive value to eliminate IBD diagnosis, good correlation to endoscopic activity and good ability to predict relapse. Recently, several teams including ours, showed that fecal biomarkers such as Chitinase 3-Like 1 (CHI3L1), matrix metalloprotease type 9 (MMP-9) and serum biomarkers neutrophil gelatinase B- complex associated lipocalin (NGAL)-MMP9 and serum CHI3L1 could be better biomarkers than fecal calprotectin to assess endoscopic activity in patients with UC.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
62
Start Date
2021-06-25
Completion Date
2026-06-09
Last Updated
2026-06-17
Healthy Volunteers
No
Conditions
Interventions
Serum and fecal measurements
* Serum measurements: NGAL-MMP9 and CHI3L1 * Fecal measurements: Calprotectin, CHI3L1 and MMP9
Locations (1)
CHU de Clermont-Ferrand
Clermont-Ferrand, Auvergne, France